Measurement of serum lanthanum in patients treated with lanthanum carbonate by inductively coupled plasma-mass spectrometry

Annals of Clinical Biochemistry

Volumn 48, Issue 2, 2011, Pages 178-182

  Handley, S A ^a   Raja, K B ^a   Sharpe, C ^a   Flanagan, R J ^a  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LANTHANUM; LANTHANUM CARBONATE;

ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; HEMODIALYSIS; HUMAN; MASS SPECTROMETRY; PRIORITY JOURNAL;

ADULT; AGED; BLOOD CHEMICAL ANALYSIS; DRUG CONTAMINATION; FEMALE; HUMANS; KIDNEY DISEASES; LANTHANUM; LIMIT OF DETECTION; MALE; MASS SPECTROMETRY; MIDDLE AGED; RENAL DIALYSIS; REPRODUCIBILITY OF RESULTS;

EID: 79953020385     PISSN: 00045632     EISSN: 00045632     Source Type: Journal    
DOI: 10.1258/acb.2010.010162     Document Type: Article

References (15)

1. Brancaccio D, Cozzolino M. Lanthanum carbonate: time to abandon prejudices? Kid Int 2007;71:190-2
2. Barton Pai A, Conner TA, McQuade CR. Therapeutic use of the phosphate binder lanthanum carbonate. Expert Opin Drug Metab Toxicol 2009;5:71-81
3. Sprague M, Ross A, Nath D, et al. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clin Nephrol 2009;72:252-8
4. Hutchison AJ, Barnett ME, Krause R, et al. Lanthanum Carbonate Study Group. Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease stage 5 receiving hemodialysis. Clin Nephrol 2009;71:286-95
5. Shigematsu T, Lanthanum Carbonate Research Group. One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis. Ther Apher Dial 2010;14:12-9
6. Chan WL, Rounsley K, Chapman E, et al. Lanthanum carbonate is an effective hypophosphatemic agent for hemodialysis patients intolerant of other phosphate binders. J Ren Nutr 2010;20:270-7
7. Curran MP, Robinson DM. Lanthanum carbonate: a review of its use in lowering serum phosphate in patients with end-stage renal disease. Drugs 2009;69:2329-49
8. EURACHEM Guide. The Fitness for Purpose of Analytical Methods. A Laboratory Guide to Method Validation and related Topics. 1998. See http://www.eurachem.org/guides/html/mval.htm (last checked 1 November 2010)
9. Fujimori E, Hayashi T, Inagaki K, et al. Determination of lanthanum and rare earth elements in bovine whole blood reference material by ICP-MS after co-precipitation with heme-iron as coprecipitant. Fresenius J Anal Chem 1999;363:277-82
10. Inagaki K, Haraguchi H. Determination of rare earth metals in human blood serum by inductively coupled mass spectrometry after chelating resin preconcentration. Analyst 2000;125:191-6 (Pubitemid 30064376)
11. Rodushkin I, Odman F. Assessment of the contamination from devices used for sampling and storage of whole blood and serum for element analysis. J Trace Elem Med Biol 2001;15:40-5 (Pubitemid 32927523)
12. Cornelis R, Heinzow B, Herber RF, et al. Sample collection guidelines for trace elements in blood and urine. IUPAC Commission of Toxicology. J Trace Elem Med Biol 1996;10:103-27 (Pubitemid 26235307)
13. Joy M, Finn W. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kid Dis 2003;42:96-107 (Pubitemid 36807658)
14. Spasovski G, Sikole A, Gelev S, et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow up. Nephrol Dial Transpl 2006;21:2217-24 (Pubitemid 44295048)
15. Damment S, Pennick M. Clinical pharmacokinetics of the phosphate binder lanthanum carbonate. Clin Pharmacokinet 2008;47:553-63